132 related articles for article (PubMed ID: 36193130)
1. Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer.
Ye W; Song Z; Lin Z
Evid Based Complement Alternat Med; 2022; 2022():5067402. PubMed ID: 36193130
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma.
Yang Q; Li G; Wu X; Lin H; Wu W; Xie X; Zhu Y; Cai W; Shi C; Zhuo S
Front Oncol; 2023; 13():1136366. PubMed ID: 37064142
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.
Zhao J; Zhao L; Guo W; Wang S; Tao X; Li L; Mao Y; Tan F; Gao Y; Wu N; Ying J; Xue Q; Li N; Gao S; He J
J Thorac Oncol; 2023 Jun; 18(6):780-791. PubMed ID: 36870519
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag.
He L; Chen X; Ding L; Zhang X
J Oncol; 2022; 2022():1530875. PubMed ID: 36276277
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
Zhou C; Wang Y; Zhao J; Chen G; Liu Z; Gu K; Huang M; He J; Chen J; Ma Z; Feng J; Shi J; Yu X; Cheng Y; Yao Y; Chen Y; Guo R; Lin X; Wang Z; Gao G; Wang Q; Li W; Yang X; Wu L; Zhang J; Ren S
Clin Cancer Res; 2021 Mar; 27(5):1296-1304. PubMed ID: 33323401
[TBL] [Abstract][Full Text] [Related]
7. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
Front Oncol; 2021; 11():835889. PubMed ID: 35174073
[TBL] [Abstract][Full Text] [Related]
8. Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study.
Wang J; Gao S; Yang Y; Liu X; Zhang P; Dong S; Wang X; Yao W
Cancer Manag Res; 2021; 13():8999-9005. PubMed ID: 34887682
[TBL] [Abstract][Full Text] [Related]
9. Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer.
Zhu Y; Lin Z; Wu C
Evid Based Complement Alternat Med; 2023; 2023():4242346. PubMed ID: 37089715
[TBL] [Abstract][Full Text] [Related]
10. Effect of Intensity Modulated Radiotherapy (IMRT) on the immunity, physical status and clinical effect of locally advanced NSCLC patients.
Xu JK
Pak J Med Sci; 2021; 37(5):1480-1485. PubMed ID: 34475934
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Wang D; Yang X; Long J; Lin J; Mao J; Xie F; Wang Y; Wang Y; Xun Z; Bai Y; Yang X; Guan M; Pan J; Seery S; Sang X; Zhao H
Front Oncol; 2021; 11():646979. PubMed ID: 33912461
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and biomarker exploration of camrelizumab combined with apatinib in the treatment of advanced primary liver cancer: a retrospective study.
Zeng Z; Jiang Y; Liu C; Zhu G; Ma F; Yang L; Qiu J; Tang J; Ye X; Peng T; Zeng J; Ma J
Anticancer Drugs; 2021 Nov; 32(10):1093-1098. PubMed ID: 34232941
[TBL] [Abstract][Full Text] [Related]
13. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
Xing P; Wang M; Zhao J; Zhong W; Chi Y; Xu Z; Li J
Thorac Cancer; 2021 Oct; 12(20):2825-2828. PubMed ID: 34409776
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
Li C; Yu F; Xu W
J Clin Pharm Ther; 2022 Dec; 47(12):2325-2334. PubMed ID: 36495117
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring
Gao G; Ni J; Wang Y; Ren S; Liu Z; Chen G; Gu K; Zang A; Zhao J; Guo R; He J; Lin X; Pan Y; Ma Z; Wang Z; Fan M; Liu Y; Cang S; Yang X; Li W; Wang Q; Zhou C
Transl Lung Cancer Res; 2022 Jun; 11(6):964-974. PubMed ID: 35832447
[TBL] [Abstract][Full Text] [Related]
16. The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer.
Li J; Chen Y; Wang X; Wang C; Xiao M
Transl Cancer Res; 2021 Apr; 10(4):1900-1906. PubMed ID: 35116511
[TBL] [Abstract][Full Text] [Related]
17. A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.
Zhao J; Yu H; Han T; Wang W; Tong W; Zhu X
J BUON; 2019; 24(6):2267-2272. PubMed ID: 31983093
[TBL] [Abstract][Full Text] [Related]
18. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
19. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of camrelizumab combined with chemotherapy in nonsquamous nonsmall cell lung cancer as the second-line therapy: A retrospective analysis.
Huang W; Zhang Q; Da L; Shen Y; Xiong F; Zhang C
J Cancer Res Ther; 2022 Apr; 18(2):576-580. PubMed ID: 35645130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
